Breaking News, Financial News

Financial Report: Elan 3Q

Early stage business restructuring impacts earnings

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan 3Q Revenues: $306.6 million (+10%) 3Q Loss: $13.7 million (earnings were $670.6 million in 3Q11)* YTD Revenues: $883.0 million (+11%) YTD Loss: $30.2 million  (earnings were $755.2 million YTD11) Comments: Tysabri global in-market sales grew 3% to $403.8 million, reflecting a 17% growth in U.S. sales of Tysabri, offset by an 11% decrease in the rest of world. Loss in the quarter includes charges of $111.3 million related to the separation of the Neotope business and the discontinuation...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters